Chhabria, Karishma
Selvaraj, Sudhakar
Refuerzo, Jerrie
Truong, Chau
Cazaban, Cecilia Ganduglia
Article History
Received: 3 March 2023
Accepted: 25 April 2024
First Online: 7 June 2024
Declarations
:
: The study was reviewed and approved by the University of Texas Health Science Center at Houston institution’s review board (protocol number HSC-SPH-20-0073). The need for written informed consent was waived by the University of Texas Health Science Center at Houston ethics committee due to the retrospective and anonymous nature of the study. All methods were carried out in accordance with relevant guidelines and regulations.
: Not Applicable.
: Sudhakar Selvaraj has received research support as Principal investigator for Flow Neuroscience and study/sub investigator for clinical research, Compass Pathways, LivaNova, Janssen and Relmada, and has received speaking honoraria from the British Medical Journal Publishing Group and Psychiatry Education Forum. He has received consultant fee for data safety monitoring board membership from Worldwide clinical trials/Inversago and Vicore pharma. Sudhakar Selvaraj is a full time employee of Intra-Cellular Therapies (ITI) Inc. ITI has no role in the design, conduct, analysis or publication of this manuscript. The remaining authors do not have any competing interests.